New drug could help heart transplant patients avoid rejection
NCT ID NCT04477629
First seen Jan 07, 2026 · Last updated May 20, 2026 · Updated 21 times
Summary
This study tests whether belatacept, an anti-rejection drug, is safe for adults who have received a new heart. Researchers will monitor 12 participants for serious side effects like organ rejection, infections, or graft failure. The goal is to find a better way to manage the immune system after a heart transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART TRANSPLANTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Columbia University
ACTIVE_NOT_RECRUITINGNew York, New York, 10032, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.